Please join me for a dinner meeting and program entitled “Hot Topics in Cirrhosis.”  The programs will focus on the coordinated application of a CLDF endorsed evidence-based algorithm in the in-patient and ambulatory setting with the goal of improving patient …

June 12, 2019, marks the second annual International NASH Day. First held in 2018 by the Global Liver Institute, International NASH Day advocates for raising liver health awareness and promoting early intervention for fatty liver disease and NASH, its more …

As you may have noticed, The Institute for Liver Health has undergone a name change and updated its name to Arizona Liver Health™. The change comes with our desire to serve more patients in Arizona and establish our practices among …

Content sourced from HepMag.com A placebo-controlled study of obeticholic acid showed it improved liver fibrosis with no worsening of non-alcoholic steatohepatitis. An advanced trial of Intercept Pharmaceuticals’ experimental non-alcoholic steatohepatitis (NASH) treatment found it improved liver fibrosis with no worsening …

Article sourced from Zachry WM, et al. Abstract 27. Presented at: American College of Gastroenterology Annual Scientific Meeting; Oct. 5-10, 2018; Philadelphia. PHILADELPHIA — FibroScan screening for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis could significantly improve patient diagnosis and care, …

Content sourced from Hepmag.com As pharmaceutical companies race to develop treatments for NASH, they find one thing is missing: willing test subjects. As the rate of liver disease continues to rise along with the rate of obesity, more than a …